Cadrenal Therapeutics (CVKD) investor relations material

Executive summary

• Focused on advancing therapies for critical care cardiology and orphan cardiovascular conditions, with a pipeline including CAD-1005, tecarfarin, frunexian, and CAD-2000.

• Achieved key clinical and regulatory milestones, including late-breaking Phase 2 data for CAD-1005 showing >25% reduction in thrombotic events and favorable safety profile, FDA guidance for a Phase 3 trial, and submission for Rare Pediatric Disease Designation for tecarfarin.

• Shifted strategy to prioritize out-licensing, partnerships, and portfolio monetization due to capital constraints, launching a structured strategic partnering process.

Financial highlights

• Net loss for Q2 2026 was $3.3 million, improved from $3.7 million in Q2 2025; net loss for the six months ended June 30, 2026 was $5.8 million, a 23% improvement year-over-year.

• Research and development expenses for Q2 2026 were $0.7 million, down from $1.1 million year-over-year; general and administrative expenses were $2.6 million, slightly down from $2.7 million.

• Cash and cash equivalents were $2.4 million as of June 30, 2026, increasing to $4.2 million by early August 2026 after a PIPE/private placement.

• Cash used in operating activities was $5.2 million for the six months ended June 30, 2026.

Outlook and guidance

• Current cash resources are expected to fund operations through Q1 2027, but are insufficient to advance product candidates to clinical trial readiness or to commence/complete any clinical trials.

• Management is seeking additional funding through strategic partnerships, out-licensing, grants, equity, or debt, but there is substantial doubt about the ability to continue as a going concern for the next 12 months.

• No plans to independently fund or execute late-stage Phase 3 clinical trials; focus remains on early- to mid-stage validation and partnership opportunities.